Ren Zixuan, Zheng Zhihuan, Feng Xiujing
Shandong Provincial Key Laboratory for Rheumatic Disease and Translational Medicine, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China.
School of Clinical and Basic Medical Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Gut Microbes. 2024 Jan-Dec;16(1):2440125. doi: 10.1080/19490976.2024.2440125. Epub 2024 Dec 10.
Acute lung injury (ALI) is an acute, diffuse inflammatory lung condition triggered by factors of severe infections, trauma, shock, burns, ischemia-reperfusion, and mechanical ventilation. It is primarily characterized by refractory hypoxemia and respiratory distress. The more severe form, acute respiratory distress syndrome (ARDS), can progress to multi-organ failure and has a high mortality rate. Despite extensive research, the exact pathogenesis of ALI and ARDS remains complex and not fully understood. Recent advancements in studying the gut microecology of patients have revealed the critical role that gut microbes play in ALI/ARDS onset and progression. While the exact mechanisms are still under investigation, evidence increasingly points to the influence of gut microbes and their metabolites on ALI/ARDS. This review aims to summarize the role of gut microbes and their metabolites in ALI/ARDS caused by various triggers. Moreover, it explores potential mechanisms and discusses how gut microbe-targeting interventions might offer new clinical strategies for the treatment of ALI/ARDS.
急性肺损伤(ALI)是一种由严重感染、创伤、休克、烧伤、缺血再灌注和机械通气等因素引发的急性、弥漫性炎症性肺部疾病。其主要特征为难治性低氧血症和呼吸窘迫。更为严重的形式即急性呼吸窘迫综合征(ARDS),可进展至多器官功能衰竭,且死亡率很高。尽管进行了广泛研究,但ALI和ARDS的确切发病机制仍然复杂,尚未完全明确。近期对患者肠道微生态的研究进展揭示了肠道微生物在ALI/ARDS发病和进展中所起的关键作用。虽然确切机制仍在研究中,但越来越多的证据表明肠道微生物及其代谢产物对ALI/ARDS有影响。本综述旨在总结肠道微生物及其代谢产物在各种诱因所致ALI/ARDS中的作用。此外,还探讨了潜在机制,并讨论了针对肠道微生物的干预措施如何可能为ALI/ARDS的治疗提供新的临床策略。
Front Immunol. 2025-2-14
Biomed Pharmacother. 2024-6
Front Cell Infect Microbiol. 2025-8-11
Chin Med J Pulm Crit Care Med. 2024-2-3
Signal Transduct Target Ther. 2024-1-17
Gut Microbes. 2023-12
Front Immunol. 2023